
e-therapeutics: Computing the Future of Medicine
Biotechnology Research
Executive Summary
Investment Thesis
Overview of buy and sell case of the business.
Why Invest?
Key pieces of information about the business that you need to know about.
The Mission
Industry Leader
Novel pipeline
Catalysts
The key events that could drive investment opportunities and shift markets.
Follow the Experts
Quickly navigate key insights from industry experts and leverage their knowledge and market intelligence.

Expert Insights

Expert Insights

Expert Insights

Expert Insights

Expert Insights

Expert Insights
Investor Materials
Access the most recent investor updates published by the company.
Key Investor Materials
Press releases
ArticleFiling of four new patent applications
Investor Presentation Feb 2024
PDFAnnual Report 2023
PDFExternal Insights
A curated collection of third-party content relevant to the company and sector to help inform your investment decision.
AI & Drug Discovery
How to enable AI in drug discovery where there's no big data | Tian Cai | TEDxBoston
ArticleEnjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.
RNAi
20th Anniversary of RNA Interference in Mammalian Cells - Oligonucleotide Therapeutics Society
ArticleThe groundbreaking discovery of RNA interference by Craig Mello and Andrew Fire was swiftly followed by the discovery of RNAi as a gene-silencing mechanism in mammalian cells. Since these breakthroughs, members of our community have devoted their lives to building on these exciting discoveries, and together we are producing results that greatly improve the quality
Team
Meet the experienced professionals leading our organization

Ali Mortazavi

Alan Whitmore

Timothy Bretherton

Laura Roca-Alonso
What the Pro's Are Asking
Here are the questions that professional investors are asking before making an investment decision.
Why should investors care about ETX?
What challenges is ETX facing?
Secondly, Bio-technology sector is undergoing a correction leading to more cautious behaviour by potential partners and investors in the near-term.